Chris H. Takimoto, M.D., Ph.D., F.A.C.P
2021
In 2021, Chris H. Takimoto, M.D., Ph.D., F.A.C.P earned a total compensation of $8.5M as Chief Medical Officer at IGM Biosciences.
Compensation breakdown
| Non-Equity Incentive Plan | $207,000 |
|---|---|
| Option Awards | $7,456,110 |
| Salary | $193,409 |
| Stock Awards | $599,900 |
| Total | $8,456,419 |
FACP received $7.5M in option awards, accounting for 88% of the total pay in 2021.
FACP also received $207K in non-equity incentive plan, $193.4K in salary and $599.9K in stock awards.
Rankings
In 2021, Chris H. Takimoto, M.D., Ph.D., F.A.C.P's compensation ranked 1,338th out of 12,415 executives tracked by ExecPay. In other words, FACP earned more than 89.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,338 out of 12,415 | 89th |
Division Manufacturing | 479 out of 5,501 | 91st |
Major group Chemicals And Allied Products | 175 out of 2,371 | 93rd |
Industry group Drugs | 146 out of 2,092 | 93rd |
Industry Pharmaceutical Preparations | 96 out of 1,542 | 94th |
Source: SEC filing on April 27, 2022.
FACP's colleagues
We found three more compensation records of executives who worked with Chris H. Takimoto, M.D., Ph.D., F.A.C.P at IGM Biosciences in 2021.